Neutropenia in primary immunodeficiency

Area of Science:

• Immunology
• Genetics
• Hematology

Background:

• Neutropenia is a common characteristic of several primary immunodeficiency diseases (PIDDs).
• The rarity and diverse pathophysiology of PIDDs often result in limited data, necessitating empirical treatment approaches.
• Recent advancements in understanding neutropenia within PIDDs warrant a comprehensive review of current data.

Purpose of the Study:

• To review recent developments in the understanding of neutropenia in primary immunodeficiency diseases.
• To highlight expanding knowledge of genetic causes and clinical presentations of neutropenia in PIDDs.
• To discuss current and potential therapeutic strategies for neutropenia in PIDDs.

Main Methods:

• Literature review of recent studies on neutropenia in PIDDs.
• Analysis of genetic mutations associated with neutropenia.
• Evaluation of clinical manifestations and treatment outcomes.

Main Results:

• The spectrum of severe congenital neutropenia continues to expand with new genetic discoveries, including mutations in G6PC3.
• Hypotheses regarding C16orf57 gene function may explain overlaps between different marrow diseases.
• Plerixafor shows potential in treating warts, hypogammaglobulinemia, infection, and myelokathexis syndrome (WHIM) syndrome.
• Neutropenia is a feature in adenosine deaminase-deficient severe combined immunodeficiency, with increased susceptibility to myelotoxins.
• Granulocyte-colony stimulating factor (G-CSF) is the primary treatment for neutropenia in PIDDs, while hematopoietic cell transplantation offers a cure.

Conclusions:

• The number of primary immunodeficiency diseases associated with neutropenia is growing.
• Understanding of the diverse phenotypes and underlying pathophysiology of neutropenia in PIDDs has significantly advanced.
• New data and hypotheses are emerging to explain the varied presentations of neutropenia in PIDDs.